Summary. Background. The COVID‐19 frequency among pregnant women is comparable to general population but it requires specific approach due to increased risk of maternal mortality as a result of infectious complications. The hypercoagulation is during physiological pregnancy, and COVID‐19 can enhance further a procoagulant conditions. In such cases the anticoagulant therapy is aimed to reduce the thrombotic risk. Patients/Methods. The article presents 2 clinical cases of successful use of anticoagulants (low molecular weight heparin) in pregnant women with confirmed COVID‐19. Results. A retrospective analysis of laboratory and clinical data has demonstrated the efficacy of parnaparin sodium as a means of preventing thrombotic complications in pregnant women with COVID‐19. Conclusions. Anticoagulant therapy in pregnant women with COVID‐19 allows to reduce the thrombotic risk and improve the reproductive outcomes of pregnancy. References Klok F.A., Kruip M.J., Arbous M.S. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–7. DOI: 10.1016/j.thromres.2020.04.013. Qin C., Zhou L., Hu Z. et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;71(15):762–8. DOI: 10.1093/cid/ciaa248. Thachil J., Tang N., Gando S. et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Hemost. 2020;18(5):1023–6. DOI: 10.1111/jth.14810. Bulanov A. Yu., Roitman E.V. New coronavirus infection, hemostasis and heparin dosing problems: it is important to say now. Tromboz, gemostaz i reologiya. 2020;(2):11–8. (In Russ.). DOI: 10.25555/THR.2020.2.0913. Interim guidelines «Prevention, diagnosis and therapy of new coronavirus infection (COVID-19)». Version 7 (03.06.2020). Ministerstvo zdravoohraneniya Rossijskoj Federacii, 2020. 166 pp. (In Russ.). Di Renzo G.C., Giardina I. COVID-19 in pregnancy: consider thromboembolic disorders and thromboprophylaxis. Am J Obstet Gynecol. 2020;223(1):135. DOI: 10.1016/j.ajog.2020.04.017. Zabolotskikh I.B., Kirov M. Yu., Lebedinskii K.M. et al. Anesthesia and intensive care for patients with COVID-19. Russian Federation of Anesthesiologists and Reanimatologists Guidelines. Vestnik intensivnoj terapii imeni A.I. Saltanova. 2020;(S1):3–120. (In Russ.). DOI: 10.21320/1818–474X-2020-S1–9–120. Cui S., Chen S., Li X.et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421–4. DOI: 10.1111/jth.14830. Vlachodimitropoulou K.E., Vivanti A.J., Shehata N.et al. COVID19 and acute coagulopathy in pregnancy. J Thromb Haemost. 2020;18(7):1648–52. DOI: 10.1111/jth.14856. Saviron-Cornudella R., Altamirano-Barcia I.E., Chedrauiet P. et al. Coronavirus disease 2019 (COVID-19) and human pregnancy: a scoping review. Gynecol Reprod Endocrinol Metab. 2020;1(2):70–5. Liu X., Li Z., Liu S. et al. Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction. medRxiv. 29 Feb 2020. DOI: 10.1101/2020.02.27.20027557. Lapina I.A., Gavrilov M.V., Taranov V.V. et al. Metabolic syndrome as a risk factor for vascular complications in patients with endometrial cancer. Akusherstvo i ginekologiya. 2019;(6):132–8. (In Russ.). DOI: 10.18565/aig.2019.6.132–138. Maugeri N., de Gaetano G., Miriam Barbanti M. et al. Prevention of platelet-polymorphonuclear leukocyte interactions: new clues to the antithrombotic properties of parnaparin, a low molecular weight heparin. Haematologica. 2005;90(6):833–9. Maugeri N., Di Fabio G., Barbanti M. et al. Parnaparin, a lowmolecular-weight heparin, prevents P-selectin dependent formation of platelet-leukocyte aggregates in human whole blood. Thromb Haemost. 2007;97:965–73. DOI: 10.1160/th06–12–0680.
更多
原文链接
分享
引用
